Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Eli Lilly Acquiring Prevail Therapeutics in $880 Million Deal

By Eric Volkman - Dec 15, 2020 at 3:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The buyer is also on the hook for a milestone payment that could hit $4 per share.

Eli Lilly ( LLY -0.49% ) will soon add a new asset to its portfolio. The veteran pharmaceutical company announced on Tuesday that it has signed a definitive agreement to acquire gene therapy specialist Prevail Therapeutics ( PRVL ).

The price is $22.50 per share in cash, which will be paid at the deal's closing. This values the deal at roughly $880 million. Prevail stockholders will also receive one nontradeable contingent value right (CVR) worth up to $4 per share, if and when their company receives its first regulatory approval in either the U.S., Japan, the U.K., Germany, France, Italy, or Spain.

A researcher studying a sample in a petri dish.

Image source: Getty Images.

In order to earn the full CVR, Prevail will have to win that approval by Dec. 31, 2024. Following this date, the payout will be reduced by slightly over $0.08 per month until Dec. 1, 2028. The CVR expires after that.

In its press release touting the acquisition, Eli Lilly wrote that it "will establish a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets."

Prevail currently has three drugs in development. All are aimed at combating neurodegenerative disorders such as Parkinson's and neuronopathic Gaucher disease. Two are currently being tested in clinical trials.

Considering that the $22.50 per share up-front payment alone is nearly double Prevail's closing price the day before the deal was announced, it's clear that Eli Lilly has very high hopes for the company specifically and gene therapy more generally.

Investors seem to share this ambition. In midafternoon trading on Tuesday, Eli Lilly's stock was up by 5.4%, trouncing the gains of the S&P 500 index.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$245.11 (-0.49%) $-1.22
Prevail Therapeutics Inc. Stock Quote
Prevail Therapeutics Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.